PRP vs Exosomes: An Honest Clinical Comparison

"PRP or exosomes?" is the regenerative question I get most, and the answer is usually clearer than the marketing makes it sound. These two treatments get lumped together as interchangeable regenerative options — but they differ in the one way that matters most to a nurse building a defensible practice: their track record and regulatory standing. I run regenerative protocols daily across three practices, so I'll lay out the real comparison — what each one is, where each stands with the FDA, and which a nurse should build first.

PRP is your own blood, concentrated to deliver a high platelet and growth-factor load; exosomes are externally-sourced cell-signaling particles marketed to deliver regenerative signals. The decisive difference is standing: PRP is an autologous product with a long aesthetic track record, while exosomes are investigational and not FDA-approved for aesthetic or hair use. Both aim to stimulate repair, but PRP is the more proven, more clearly-scoped, and more reproducible of the two — which is why it's the better foundation for a nurse.

*This is general educational guidance, not a clinical protocol to apply without proper hands-on training and supervision.*

Here's the comparison at a glance:

Platelet-rich plasma is made from the patient's own blood, drawn and spun in a centrifuge to concentrate the platelets. The therapeutic power comes from *concentration* — a single-spin protocol can't reach the therapeutic, supraphysiologic platelet load that regenerative results depend on, while a double-spin protocol can. Because it's the patient's own blood, minimally manipulated, PRP sits in a different and more defensible regulatory category than an externally-manufactured product. (The full PRP method — concentration, spin protocol, LR vs LP — is in our canonical PRP training guide.)

Exosomes are tiny vesicles released by cells that carry signaling molecules. In aesthetics they're sold as a way to deliver regenerative signals to skin or scalp. Unlike PRP, they're not made from the patient — they're an externally-sourced product, and product quality and concentration vary widely between sources. The biology is genuinely interesting and under active study, but the proof and the approval that would make exosomes a settled treatment aren't there yet. (Full picture: exosomes in aesthetics.)

This is the line that should drive the decision. PRP is generally handled as a minimally manipulated autologous blood product, with aesthetic uses largely off-label — a well-understood, defensible position. Exosomes are investigational and not FDA-approved for aesthetic or hair indications, and the FDA has issued public warnings about unapproved regenerative products including exosome- and stem-cell-derived ones. So a clinic offering PRP is using the patient's own blood in an established way; a clinic offering exosomes is offering an unapproved product that must be represented honestly to every patient. That's not a small difference — it's a liability and trust difference.

PRP, by track record — though neither is a miracle, and I won't pretend otherwise. PRP has years of aesthetic use behind it and a clearer mechanism story; exosome evidence is earlier and thinner. For hair specifically, I tell my own patients the same thing about both: no regenerative product regrows follicles that are already gone. PRP can support a healthier scalp environment, and the same may prove true of exosomes, but the "regrow your hair" marketing oversells both. Honest expectation-setting matters more than which product you pick.

If you only hear the marketing, you'd think exosomes are a settled wonder treatment. They aren't, and the gaps are worth naming plainly. They're investigational and not FDA-approved for aesthetic or hair use, and the FDA has issued public warnings about unapproved regenerative products — including exosome- and stem-cell-derived ones — citing contamination and serious adverse-event concerns in some cases. Because the product is manufactured externally rather than drawn from your patient, quality and concentration vary widely between sources, so one vendor's vial isn't the same as another's. And the human evidence is still early. None of that makes exosomes fraudulent. It makes them an unapproved product you'd have to represent honestly to every patient and explore only with your own legal counsel — not a vendor's compliance assurances.

The honest answer is "the biology is plausible, the proof isn't settled." Exosomes carry signaling molecules, and stimulating a collagen response is a reasonable mechanism on paper. But plausible mechanism and proven, reproducible clinical result are different things, and the large controlled human trials that would let anyone promise a collagen outcome aren't there yet. PRP has the longer track record on this front. With exosomes, "may support" is honest; "boosts your collagen" outruns the evidence.

PRP — without much hesitation. It's autologous, more proven, more clearly-scoped, more reproducible, and it teaches you the regenerative fundamentals (concentration, draw, spin protocol, indication-specific prep) that make you genuinely competent. Exosomes are the newest and least-settled option; reaching for them before you've mastered PRP is building on the shakiest part of the menu. Build PRP first, do it with real concentration science, and only explore exosomes later — with full informed consent, accurate FDA representation, and your own legal counsel. (For the full sequencing logic, see where to start with regenerative aesthetics.)

*Typical results vary, and regenerative outcomes depend on the patient, the indication, and the preparation. Nothing here is a guarantee of results, and exosome applications described are investigational.*